Abbood Zainab A, Ajeel Zainab H, Joudah Marwah S, Al-Nimer Marwan Salih M, Al-Shammari Ahmed Hamza
Department of Pharmacy, Kut University College, Al-Kut, Wasit, Iraq.
J Adv Pharm Technol Res. 2023 Jul-Sep;14(3):235-240. doi: 10.4103/JAPTR.JAPTR_242_23. Epub 2023 Jul 28.
The SARS-CoV-2 virus has the property of activating the coagulation process, which is responsible for producing thrombotic events which is considered as one of the most serious COVID-19 complications. Hypertension is a hazard factor for COVID-19 complications, and people who are treated with calcium entry blockers may halt the occurrence of thrombotic events. to evaluate the effect of amlodipine on some genes involved in the activation of the coagulation procedure in COVID-19 patients with hypertensive. observational, cross-sectional study. This study was carried out in the Department of Pharmacy at Al-Kut University College in Wasit, Iraq, in conjunction with Al Zahraa Hospital from June 2021 to March 2022. A total of 45 COVID-19 patients participated in this study who were grouped into as follows: Group I ( = 23) who had no previous history of hypertension and Group II ( = 22) who had previous hypertension and were treated with amlodipine. Expression of the calcium-sensing receptor (CaSR), coagulation factor V (F5), and methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 Like (MTHFD1L) genes was determined. values were calculated by Chi-square test for categorized facts and the Mann-Whitney test for incessant data. ≤ 0.05 was considered statistically significant. Group II patients had significantly lower levels of CaSR, F5, and MTHFD1L gene expression compared with the corresponding levels in Group I patients. The expression level of MTHFD1L was elevated significantly in patients who had currently high blood pressure compared with normotensive patients in both the groups. Amlodipine is preferred in hypertensive patients who have COVID-19 because it attenuates the levels of gene expression that have an impact on the coagulation process.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒具有激活凝血过程的特性，凝血过程会引发血栓形成事件，这被认为是冠状病毒病（COVID-19）最严重的并发症之一。高血压是COVID-19并发症的一个危险因素，而接受钙通道阻滞剂治疗的人可能会阻止血栓形成事件的发生。为了评估氨氯地平对COVID-19高血压患者凝血过程激活相关某些基因的影响。进行观察性横断面研究。本研究于2021年6月至2022年3月在伊拉克瓦西特省库特大学药学院与宰赫拉医院联合开展。共有45例COVID-19患者参与本研究，他们被分为以下两组：第一组（n = 23），既往无高血压病史；第二组（n = 22），既往有高血压病史且接受氨氯地平治疗。测定钙敏感受体（CaSR）、凝血因子V（F5）和亚甲基四氢叶酸脱氢酶（NADP+依赖）1样（MTHFD1L）基因的表达。分类数据采用卡方检验，连续数据采用曼-惠特尼检验计算P值。P≤0.05被认为具有统计学意义。与第一组患者的相应水平相比，第二组患者的CaSR、F5和MTHFD1L基因表达水平显著降低。与两组中的血压正常患者相比，目前患有高血压的患者MTHFD1L的表达水平显著升高。对于患有COVID-19的高血压患者，氨氯地平是首选药物，因为它能降低对凝血过程有影响的基因表达水平。
